• DNDi - Best Science for the Most Neglected 20 Years
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • COVID-19
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • HELP Helminth Elimination Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
DNDi - Best Science for the Most Neglected 20 Years
  • DNDi - Best Science for the Most Neglected 20 Years
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • COVID-19
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • HELP Helminth Elimination Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > Press releases

Thai partners unite with DNDi to improve access to treatments and diagnostics for people with hepatitis C in Thailand

Home > Press releases

Thai partners unite with DNDi to improve access to treatments and diagnostics for people with hepatitis C in Thailand

Doctor talking with patient during a consultation
Bangkok — 1 Jun 2022
Share on twitter
Share on facebook
Share on linkedin
Share on email
Share on print
  • English
    • English
    • ไทย

The Ministry of Public Health (MOPH) of Thailand, the National Health Security Office (NHSO) of Thailand, the Faculty of Medicine Siriraj Hospital, Mahidol University, the Thai Association for the Study of the Liver Disease (THASL), and the non-profit research organization Drugs for Neglected Diseases initiative (DNDi) have combined forces to tackle hepatitis C.

This public-health-focused collaboration, within the framework of Thailand’s National Strategic Plan on Viral Hepatitis, aims to contribute to the goal of eliminating hepatitis C (HCV) as a public health problem in Thailand by addressing persistent barriers in access to life-saving treatments and diagnostics.

HCV is known as a ‘silent killer’ because 80% of people living with the disease remain asymptomatic for years, before developing complications that can include liver disease, cirrhosis, and cancer. Although an estimated 300,000 people die from HCV every year, only a small fraction of people with the disease receive treatment. In recent years, the price of direct-acting antiviral (DAA) treatments have fallen, but not enough for countries to enable wide-scale roll-out of treatment or implement national test-and-treat strategies that could accelerate efforts to eliminate HCV as a public health problem. Early diagnosis and initiation of treatment is crucial towards preventing health problems as a result from infection and also to avoid transmission of the virus.

In the South-East Asia and Western Pacific regions, an estimated 20 million people are chronically infected with HCV. Rapid scale-up of diagnosis and treatment is vital to reducing the burden of disease, which is not decreasing globally despite the fact that simple, safe, and effective treatments have existed for nearly a decade. In Thailand, an estimated 378,000 people living with hepatitis C as of 2020, amounting to 0.5% of the population aged between 15 and 64.

‘My hope is we can achieve elimination by 2030. This partnership statement is testament to our country taking bold steps towards a patient-focused approach for hepatitis C patients. Having access to more choices of DAAs is key in Thailand’s journey towards eliminating hepatitis C by 2030. We need a strong public health approach to ensure more DAAs, including ravidasvir, are available in Thailand so that treatment is affordable for our national programme to treat more patients with hepatitis C,’ said Prof. Dr Prasit Watanapa, Dean of Faculty of Medicine Siriraj Hospital, Mahidol University, Thailand.

Thailand has a long history of efforts to tackle HCV, including a recently concluded a Phase II/III clinical trial to assess the safety, efficacy, tolerability, pharmacokinetics, and acceptability of 12- and 24-week regimens combining the DAAs, ravidasvir and sofosbuvir, which together form an affordable HCV treatment, first registered in Malaysia in 2021. The clinical trial was co-sponsored by the Ministry of Public Health of Thailand and implemented with strong support from numerous Thai partners, with the aim of bringing this new treatment regimen to the people of Thailand.

The new collaboration will work toward implementing a test-and-treat strategy for HCV in Thailand by rolling out accessible, all-oral treatment at an affordable price and scaling up community-based screening campaigns to find undiagnosed people with HCV. The partnership will also work to improve public awareness of HCV infection risks. All partners are committed to removing the barriers that prevent access to HCV diagnostics and treatments and hinder progress toward reaching the World Health Organization goal of eliminating hepatitis C by 2030.

Partners quotes

‘Integrated strategies are important to strengthen the primary healthcare facilities with the support of a patient-focused and community-driven approach. This is very important’, said Prof. Dr Prasit Watanapa, Dean of Faculty of Medicine Siriraj Hospital, Mahidol University, Thailand.

‘We strongly support and develop cooperation with network partners in the surveillance, prevention and control of diseases, as well as the delivery of appropriate care to those infected with hepatitis. Our goal is to end hepatitis by 2030, improve access to medicines – screening – treatment’, said Dr Opart Karnkawinpong, Director-General, Department of Disease Control (DDC), Ministry of Public Health (MOPH), Thailand.

‘The National Health Security Office (NHSO) support the nations effort towards eliminating hepatitis C by 2030.  HCV is one of the rare viral infections that can be eliminated via effective treatments. We will continue to support the hepatitis C patients in encouraging easy access to diagnostics and treatment that they need under the Universal Coverage Scheme (UCS) in Thailand’, said Dr Jadej Thammatacharee, Secretary-General, National Health Security Office (NHSO), Thailand.

‘HCV elimination is possible with rapid scale‐up of prevention, screening and treatment programmes. Initiatives that encourage simplification of hepatitis C testing and treatment in Thailand are welcomed’, said Prof. Pisit Tangkijvanich, M.D., President, Thai Association for the Study of the Liver (THASL), Thailand.

‘Hepatologists have key roles in expanding access to HCV care by supporting our non-specialists/primary care colleagues to embark on test and treat strategies in managing hepatitis C’, said Prof. Pisit Tangkijvanich, M.D., Thai Association for the Study of the Liver (THASL), Thailand.

‘This partnership will address the access barriers that exist in Thailand for hepatitis C treatment and ultimately help to bring more treatment options to Thai patients. To reach WHO 2030 elimination targets, Thailand must scale-up and diversify the supply of affordable DAAs’, said Jean-Michel Piedagnel, South-East Asia Regional Director, DNDi.

‘We will never achieve the 2030 hepatitis C elimination goal without political will, partnerships, and collaborations such as the one in Thailand on access to HCV treatment and therapeutics. It is important for us to work together to ensure that no patients are left behind by addressing the issue of access to medicines for hepatitis C’, said Dr Bernard Pecoul, Founder & Executive Director, DNDi.

About DNDi

The Drugs for Neglected Diseases initiative (DNDi) is a not-for-profit R&D organization working to deliver new treatments for neglected patients, in particular for sleeping sickness, Chagas disease, leishmaniasis, river blindness, mycetoma, HIV, hepatitis C, and dengue. DNDi’s ambition is to help enable widespread access to HCV treatment through the development and registration of affordable, safe, and efficacious pan-genotypic direct-acting antivirals (DAAs), and through advocacy for the policy change and political will needed to remove barriers to access to DAAs globally. dndi.org

About THASL

Thai Association for the Study of the Liver (THASL) is Thailand’s leading professional association with the main objectives in developing and disseminating knowledge and advancement in the field of liver diseases to doctors and healthcare professionals while ensuring the standard of treatment on par with international standards.  THASL has regularly organized trainings and encourage local academics, doctors and healthcare professionals to advance in research relating to liver diseases. Moreover, the association has also worked closely to support Liver Foundation of Thailand in communicating accurate information for better understanding about liver diseases to general public. thasl.org

About National Health Security Office (NHSO), Thailand

The National Health Security Office (NHSO), Thailand, established in 2002, was set up as a public organisation that responds to the management system that is efficient and knowledge-based for the public good. It also strives to be part of developing the nation’s sustainability in orientation of public benefits as its ultimate goal. Our responsibility is to create good health security for everyone, whereby – “Everyone who lives in Thailand is covered by the Universal Health Coverage (UHC). This helps to ensure that they have access to healthcare with confidence when needed”. The National Health Security Office (NHSO), Thailand is responsible for the development of a desirable health care service system, covered by the UHC, which are easily accessible via an effective communication and information system. This will help the NHSO to continuously improve its work on an evidence-based system for health care delivery and enabling the beneficiary registration facility, according to their convenience, necessity, monitoring and evaluation system. nhso.go.th

About Ministry of Public Health (MOPH), Department of Disease Control (DDC), Thailand

moph.go.th

About Faculty of Medicine Siriraj Hospital, Mahidol University

Faculty of Medicine Siriraj Hospital, Mahidol University, is Thailand’s first public hospital and top medical school. Since its conception, its missions have always been to provide the best healthcare service, produce quality graduates, clinicians, and medical researchers, and conduct high-impact research with implications to medical practice. This revere medical institution with high-experienced expert faculties in various specialties provides exceptional quality and up-to-date medical services with international standards. Located in Bangkok, the capital of Thailand, Siriraj is currently the largest referral center of the country. Over the years, Siriraj has gained trust among Thai people with the mission in providing good health and better quality of life for everyone. si.mahidol.ac.th

Media contacts

DNDi South-East Asia
Molly Jagpal
mjagpal@dndi.org

DNDi Geneva office
Frederic Ojardias
fojardias@dndi.org

Photo credit: Kitjapat Natthapisut-DNDi

Partnership Hepatitis C

Read, watch, share

Loading...
Patient with healthcare worker in hospital
Press releases
30 Mar 2023

Eumycetoma: DNDi welcomes Japan’s GHIT Fund support for registration of new treatment for deeply neglected fungal disease

Davide Paparo and Ian Hausler with their thermotherapy device "CLARA"
Stories
16 Mar 2023

Cutaneous leishmaniasis: Swiss students develop innovative thermotherapy device for safer treatment of ‘flesh-eating parasite’

Stories
8 Mar 2023

Highlighting gender-based treatment gaps on International Women’s Day: Mary Alamak’s story

DNDi-GARDP Southern Africa director, Carol Ruffell (left), presents the December 2022 edition of HIV Nursing Matters and the 2022 paediatric ARV dosing chart to Bénédicte Schutz, Monaco’s Director of International Cooperation (centre), and Yordanos Pasquier, Monaco’s Deputy Director of International Cooperation (right).
News
3 Mar 2023

Working together to ensure optimal treatment for children living with HIV in South Africa

Nurse with patient
Press releases
1 Mar 2023

Fiocruz and DNDi sign strategic alliance agreement

Statements
28 Feb 2023

DNDi’s submission to the Technical Assessment component of the first Global Stocktake

Statements
22 Feb 2023

DNDi comments on the zero draft of the WHO CA+ for consideration of the Intergovernmental Negotiating Body at INB4 & 5

Hat Platform Newsletter N°22 screenshot
Publications
22 Feb 2023

HAT Platform Newsletter No. 22

VIEW ALL

Help neglected patients

To date, we have delivered twelve new treatments, saving millions of lives.

Our goal is to deliver 25 new treatments in our first 25 years. You can help us get there. 

GIVE NOW
DNDi - Best Science for the Most Neglected 20 Years
Facebook-f
Twitter
Instagram
Linkedin-in
Youtube
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • Neglected tropical diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License   
We use cookies to track our audience and improve our content. By clicking 'Accept All', you are agreeing to our use of cookies. Click on 'Customize' to accept only some cookies.
Customize
REJECT ACCEPT ALL
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-advertisement1 yearSet by the GDPR Cookie Consent plugin, this cookie is used to record the user consent for the cookies in the "Advertisement" category .
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
CookieLawInfoConsent1 yearRecords the default button state of the corresponding category & the status of CCPA. It works only in coordination with the primary cookie.
PHPSESSIDsessionThis cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
CookieDurationDescription
elementorneverThis cookie is used by the website's WordPress theme. It allows the website owner to implement or change the website's content in real-time.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
CookieDurationDescription
_ga2 yearsThe _ga cookie, installed by Google Analytics, calculates visitor, session and campaign data and also keeps track of site usage for the site's analytics report. The cookie stores information anonymously and assigns a randomly generated number to recognize unique visitors.
_ga_16Q5RH3XRG2 yearsThis cookie is installed by Google Analytics.
_gat_UA-10302561-11 minuteA variation of the _gat cookie set by Google Analytics and Google Tag Manager to allow website owners to track visitor behaviour and measure site performance. The pattern element in the name contains the unique identity number of the account or website it relates to.
_gid1 dayInstalled by Google Analytics, _gid cookie stores information on how visitors use a website, while also creating an analytics report of the website's performance. Some of the data that are collected include the number of visitors, their source, and the pages they visit anonymously.
_hjAbsoluteSessionInProgress30 minutesHotjar sets this cookie to detect the first pageview session of a user. This is a True/False flag set by the cookie.
_hjFirstSeen30 minutesHotjar sets this cookie to identify a new user’s first session. It stores a true/false value, indicating whether it was the first time Hotjar saw this user.
_hjIncludedInPageviewSample2 minutesHotjar sets this cookie to know whether a user is included in the data sampling defined by the site's pageview limit.
_hjIncludedInSessionSample2 minutesHotjar sets this cookie to know whether a user is included in the data sampling defined by the site's daily session limit.
_hjSession_112884430 minutesHotjar sets this cookie.
_hjSessionUser_11288441 yearHotjar sets this cookie.
CONSENT2 yearsYouTube sets this cookie via embedded youtube-videos and registers anonymous statistical data.
Targeting
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
SAVE & ACCEPT
Powered by CookieYes Logo